FDA’s approval of Aimovig offers a ray of hope for migraine patients
Category: #health  By Saipriya Iyer  Date: 2018-05-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA’s approval of Aimovig offers a ray of hope for migraine patients

In what may seem to be breakthrough in the healthcare space, the U.S. FDA has scarcely approved Aimovig, a drug developed by Novartis & Amgen to prevent migraine. Medical experts believe that the strategic move will open up a new horizon in migraine treatment, proving to be highly beneficial for chronic migraine patients who consistently suffer from the most severe kind of headache.

For the record, the newly approved medicine is basically an injection – a device that looks similar to an insulin pen and would be required to be taken on a monthly basis. It has been speculated that the drug may cost USD 6900 for a patient annually and would be made available to migraine patients within seven days.

Reportedly, migraine is a fairly common health issue across the globe, however, the ailment is so severe that it renders patients disabled and in despair. No perfect medication has been discovered so far that is capable enough to prevent migraine attacks in patients, though certain medicines are able to reduce the severity of the pain – nearly to fifty percent or even more. Sources claim that till date, medicines developed to reduce the severity of migraine are designed to treat other ailments such as hypertension. However, it was found that these drugs were less effective against migraine and could only provide temporary relief to patients in addition to rendering serious side-effects.

As per the clinical tests conducted on patients, Aimovig reported no side-effects as compared to the placebo treatment. However, the side-effects of the drug over an elongated period among the patients suffering from severe migraine pain remained to be measured.

Healthcare service providers believe that the FDA’s approval for this innovative drug will help in effectively treating nearly 2.8 million U.S. patients who suffer from extreme migraine frequency. The organization’s nod for the drug with no side-effects is likely to prove beneficial for chronic migraine patients in the near future.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...